3-氟-3-(三氟甲基)-[1,1-联苯]-4-羧酸 | 926222-59-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氟-3-(三氟甲基)-[1,1-联苯]-4-羧酸
• 中文别名: 2-氟-4-(3-三氟甲基苯基)苯甲酸
• 英文名称: 3-fluoro-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxylic acid
• 英文别名: 2-Fluoro-4-(3-trifluoromethylphenyl)benzoic acid；2-fluoro-4-[3-(trifluoromethyl)phenyl]benzoic acid
• CAS: 926222-59-5
• 化学式: C₁₄H₈F₄O₂
• mdl: MFCD09042339
• 分子量: 284.21
• InChiKey: FOMRSNDIYBAOSO-UHFFFAOYSA-N

物化性质

• 沸点：
  370.5±42.0 °C(Predicted)
• 密度：
  1.386±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  3-氟-3-(三氟甲基)-[1,1-联苯]-4-羧酸 在 草酰氯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-Fluoro-4-[3-(trifluoromethyl)phenyl]benzoyl chloride
  参考文献：
  名称：

  A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors

  摘要：

  Distinct from previously reported urea and amide inhibitors of soluble epoxide hydrolase (sEH), a novel class of inhibitors were rationally designed based on the X-ray structure of this enzyme and known amide inhibitors. The structure-activity relationship (SAR) study was focused on improving the sEH inhibitory activity. Aminobenzisoxazoles emerged to be the optimal series, of which a potent human sEH inhibitor 7t was identified with a good pharmacokinetics (PK) profile. The strategy of employing aminoheterocycles as amide replacements may represent a general approach to develop mimics of known hydrolase or protease inhibitors containing an amide moiety. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.08.006
• 作为产物：
  描述：

  3-(三氟甲基)苯硼酸 、 4-溴-2-氟苯甲酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride caesium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 3.0h， 生成 3-氟-3-(三氟甲基)-[1,1-联苯]-4-羧酸
  参考文献：
  名称：

  AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

  摘要：

  揭示了用于治疗各种疾病、综合症、症状和紊乱的化合物、组合物和方法，包括疼痛。这些化合物及其对映体、顺反异构体和药用盐由以下式(I)所代表：其中Y、Z、R1和R2在此处定义。

  公开号：

  US20120101081A1
• 作为试剂：
  描述：

  、 3-(三氟甲基)苯硼酸 、 Dicaesio carbonate 、 1,4-二氧六环 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 甲醇 、 3-氟-3-(三氟甲基)-[1,1-联苯]-4-羧酸 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 3-氟-3-(三氟甲基)-[1,1-联苯]-4-羧酸
  参考文献：
  名称：

  Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors

  摘要：

  本发明涉及用于治疗各种疾病、综合征、状况和障碍，包括疼痛的化合物、组合物和方法。这些化合物及其对映体、二对映异构体和药学上可接受的盐由以下式(I)表示：其中，Y、Z、R1和R2在此定义。

  公开号：

  US08575363B2

文献信息

• [EN] NOVEL AGENTS TARGETING CYP51<br/>[FR] NOUVEAUX AGENTS CIBLANT CYP51
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015048306A1

  公开（公告）日：2015-04-02

  The invention provides inhibitors of a sterol C14-demethylase, a new series of 4- aminopyridyl-based lead inhibitors targeting Trypanosoma cruzi CYP51 (TcCYP51) developed using structure-based drug design as well as structure -property relationship (SPR) analyses. The screening hit starting point, LP 10 (KD < 42 nM; EC50 of 0.65 μΜ), has been optimized to give the potential leads that have low nanomolar binding affinity to TcCYP51 and significant activity against T. cruzi amastigotes cultured in human myoblasts. Many of the optimized compounds have improved microsome stability, and most are selective against the T. cruzi CYP51 relative to human CYPs 1A2, 2D6 and 3A4 (<50% inhibition at 1 μΜ). A rationale for the improvement of microsome stability and selectivity of inhibitors against human metabolic CYP enzymes is presented. In addition, the binding mode of several compounds of the invention with the T. brucei CYP51 (TbCYP51) ortholog has been characterized by x-ray structure analysis. Orally active compounds and their cyclodextrin complexes have been shown to be effective against Chagas-infected mice.

  该发明提供了一种甾醇C14-去甲基酶的抑制剂，这是一种新系列基于4-氨基吡啶的首选抑制剂，通过基于结构的药物设计以及结构-性质关系（SPR）分析来瞄准Trypanosoma cruzi CYP51（TcCYP51）而开发的。筛选起始点LP 10（KD < 42 nM；EC50为0.65 μΜ）已经经过优化，产生了具有低纳摩尔级别结合亲和力和对在人类肌细胞培养的T. cruzi游离体的显著活性的潜在首选抑制剂。许多经过优化的化合物具有改善的微粒体稳定性，大多数相对于人类CYPs 1A2、2D6和3A4对T. cruzi CYP51具有选择性（在1 μΜ下<50%的抑制）。提出了改善微粒体稳定性和抑制剂对人类代谢CYP酶的选择性的理由。此外，通过X射线结构分析表征了该发明的几种化合物与T. brucei CYP51（TbCYP51）同源物的结合方式。口服活性化合物及其环糊精复合物已被证明对克氏病感染的小鼠有效。
• AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Zhang Yue-Mei

  公开号：US20120101081A1

  公开（公告）日：2012-04-26

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (I) as follows: wherein Y, Z, and R 1 , and R 2 are defined herein.

  揭示了用于治疗各种疾病、综合症、症状和紊乱的化合物、组合物和方法，包括疼痛。这些化合物及其对映体、顺反异构体和药用盐由以下式(I)所代表：其中Y、Z、R1和R2在此处定义。
• US8575363B2
  申请人：——

  公开号：US8575363B2

  公开（公告）日：2013-11-05
• US8748417B2
  申请人：——

  公开号：US8748417B2

  公开（公告）日：2014-06-10
• [EN] AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS<br/>[FR] AMINO-PYRROLIDINE-AZÉTIDINE DIAMIDES UTILISÉS COMME INHIBITEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012054721A1

  公开（公告）日：2012-04-26

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (I) as follows: (I) wherein Y, Z, and R1 and R2 are defined herein.